Ponatinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1338 publications

Ichthyosiform pityriasis rubra pilaris-like eruption induced by ponatinib, successfully treated with topical vitamin D3 ointment.

Ichthyosiform pityriasis rubra pilaris-like eruption induced by ponatinib, successfully treated with topical vitamin D3 ointment.

Journal: European journal of dermatology : EJD

Published: May 25, 2026

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 08, 2026

Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice.

Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice.

Journal: Science translational medicine

Published: May 06, 2026

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

Journal: medRxiv : the preprint server for health sciences

Published: May 04, 2026

Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Journal: American journal of clinical oncology

Published: April 30, 2026

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.

Journal: Future medicinal chemistry

Published: April 21, 2026

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: April 16, 2026

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Leukemia & lymphoma

Published: April 09, 2026

Response by Stepanian and Jaffe to Letters Regarding Article, "Ponatinib, but Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Response by Stepanian and Jaffe to Letters Regarding Article, "Ponatinib, but Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Liu and Li Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Liu and Li Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Zheng et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Zheng et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Xu et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Xu et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Showing 1-12 of 1,338

Last Updated: 06/30/2026